Overview Open-Label Extension for Subjects Who Previously Completed Phase 3 Study ISEE2008. Status: Not yet recruiting Trial end date: 2025-01-01 Target enrollment: Participant gender: Summary Patients who completed Study ISEE2008 (GATHER2) and consent to participate will be administered monthly avacincaptad pegol 2 mg. Phase: Phase 3 Details Lead Sponsor: IVERIC bio, Inc.